Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 February 2022 | Story Lacea Loader

On the morning of 23 February 2022, some of the entrance gates to the Bloemfontein Campus were blocked by groups of protesting students. The gates were cleared by members of Protection Services and traffic could continue to enter and exit the campus.

Sporadic disruption of classes occurred during the course of the day, with several students being arrested by the South African Police Service (SAPS) for disruption of classes, which is contravention of the interdict.

The disruptive behaviour stems from students’ unhappiness with the response to the memorandum handed to the university management by the Bloemfontein Campus Central Student Representative Council (CSRC) on 21 February 2022. Also on 21 February, a memorandum was handed to the management of the Qwaqwa Campus by the campus’ CSRC. The Qwaqwa Campus was temporarily closed yesterday, following violent protest action this week; the date for the reopening of the campus will be communicated in due course. 

Today’s disruptive behaviour demonstrated by the group of students on the Bloemfontein Campus is condemned and will not be tolerated.

During this week and on numerous occasions before that, the university management has been in extensive engagements with the CSRCs on both campuses; concessions were made where possible, as was demanded in the two memoranda. However, the responses given, and the concessions made by the university were not accepted by the student leadership of the Bloemfontein Campus CSCR in particular, with more demands being made.


Concessions from the beginning of 2022:

To ensure that students register successfully for the 2022 academic year, the UFS has granted a number of financial concessions to students since the beginning of the year. The financial support given was specifically intended to fast-track the registration process of students with outstanding debt, and those awaiting confirmation of funding from the National Student Financial Aid Scheme (NSFAS). 

These concessions included:

  • Allowing students who have previously registered for foundation programmes and those who have continued with mainstream programmes to register without the prerequisite of a first payment. The provision was granted to students who applied with the N+ rule and whose respective foundation programmes are included in the Department of Higher Education and Training-funded list.
  • Permitting students with outstanding debt of up to R25 000 and who await NSFAS funding to register provisionally.
  • The university also allowed conditional registration for first-time entering students, giving those who have applied for NSFAS funding until 28 February 2022 to finalise their registration. First-time entering students, both residential and non-residential, could register conditionally, provided that they pay an amount of R500.

Demands in the two memoranda received from the CSRCs on the Bloemfontein and Qwaqwa Campuses included matters such as private accommodation; emergency accommodation; catch-up plans for students who have not yet registered; a registration threshold increase to R30 000; NSFAS allowances; and the extension of registration for international students without study permits. The Bloemfontein Campus CSRC did not accept the university’s responses to the memorandum.

The university management will continue engaging with the SRC.

Safety measures in place:

The situation on the Bloemfontein Campus is closely monitored. Protection Services is on high alert and continues to work closely with the SAPS to ensure stability on the campus.

 

Issued by:
Lacea Loader
Director: Communication and Marketing
University of the Free State
loaderl@ufs.ac.za

23 February 2022

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept